Current Evidence on Therapeutic Approaches to BCBM: Local Therapy and HER2-Positive Disease

Download this slideset for an expert-curated overview of the latest clinical data informing optimal local management of breast cancer brain metastases along with a review of the evolving role for systemic therapy in the treatment of HER2-positive CNS disease.
Lee Schwartzberg, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.38 MB
Released: December 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Puma Biotechnology, Inc.

Related Content

Prof. Dr. Arndt Hartmann, Prof. Dr. Arndt Hartmann has disclosed that he has received consulting fees from Agilent, AstraZeneca, Bristol-Myers Squibb, Diaceutics, Janssen, MSD, Pfizer, and Roche. Released: April 9, 2021

Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer in a webcast presented by Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

Experts discuss their practices with CDK4/6 and PI3K inhibitors for patients with breast cancer in today’s clinic from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 23, 2021

Downloadable short slideset from CCO on the use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue